Tauroursodeoxycholic acid (TUDCA) has an established research record in inherited retinal degeneration, where it protects photoreceptors in animal models of retinitis pigmentosa. Age-related macular degeneration (AMD) is a distinct condition—it centers on the retinal pigment epithelium (RPE), the support layer beneath the photoreceptors, rather than a primary photoreceptor gene defect. A growing but still early body of research asks whether TUDCA’s RPE-protective and antioxidant properties are relevant to AMD specifically, not just to inherited retinal disease.
This article reviews what the evidence shows about TUDCA and AMD-relevant mechanisms: RPE oxidative stress, phagocytosis of photoreceptor outer segments, and the one available human epidemiological signal for the closely related bile acid UDCA. Nothing here constitutes medical advice.
Key Takeaways
- AMD and the inherited retinal degeneration TUDCA is best studied for (retinitis pigmentosa) are different diseases; TUDCA’s AMD-relevant evidence is smaller and more recent, centered on the RPE rather than photoreceptor gene defects.
- A 2025 cell-culture study found TUDCA induces autophagy in RPE cells and protects them against oxidative stress, a core driver of AMD pathology [1].
- TUDCA has been shown to promote RPE phagocytosis of photoreceptor outer segments via MerTK receptor activation — a process that, when impaired, contributes to the drusen buildup characteristic of AMD [2].
- A 2025 retrospective human study found oral use of the closely related bile acid UDCA (TUDCA’s non-taurine-conjugated parent compound) was associated with a lower rate of newly diagnosed AMD [3], the first human-population signal for this drug class and AMD.
- No randomized controlled trial has tested TUDCA itself as a treatment for diagnosed AMD in humans; current evidence is mechanistic (cell/animal) plus one bile-acid-class epidemiological association.
Why AMD Is a Different Question Than TUDCA’s Retinitis Pigmentosa Evidence
TUDCA’s best-documented retinal research targets inherited retinal degenerations like retinitis pigmentosa, where a genetic mutation drives progressive photoreceptor death and TUDCA acts primarily as a photoreceptor-protective, anti-apoptotic agent. AMD has a different primary lesion: the retinal pigment epithelium, a single layer of cells responsible for recycling photoreceptor outer segments, transporting nutrients, and absorbing stray light. RPE dysfunction, oxidative damage, and the accumulation of cellular debris (drusen) beneath the RPE are the hallmarks of early AMD, well before photoreceptors themselves are lost.
Because TUDCA’s mechanisms — antioxidant activity, ER stress reduction, anti-apoptotic signaling — are not specific to photoreceptors, researchers have begun asking whether they also apply to the RPE cells that fail first in AMD. That is a mechanistically plausible but separate question from the retinitis pigmentosa evidence, and it deserves its own evaluation rather than being assumed to carry over automatically.
TUDCA and Oxidative Stress in the Retinal Pigment Epithelium
Oxidative stress is a central driver of RPE aging and AMD progression: the RPE sits directly beneath the photoreceptors and is exposed to constant light exposure, high oxygen demand, and the byproducts of daily outer-segment phagocytosis, making it especially vulnerable to cumulative oxidative damage over decades. A 2025 study examined TUDCA’s effect on cultured retinal pigment epithelial cells exposed to oxidative stress and found that TUDCA induced autophagy — the cell’s internal waste-clearance and recycling process — and that this autophagy induction was protective against oxidative damage [1].
The researchers traced the mechanism to Atg5-dependent autophagy operating independently of the mTORC1/mTORC2 pathways that regulate autophagy in many other cell types [1]. This is a cell-culture (in vitro) finding, not a human or even whole-animal AMD model result, so it establishes biological plausibility rather than clinical efficacy. It does, however, directly connect TUDCA to the specific cell type and specific stressor (oxidative damage) that define early AMD pathology, which is more targeted than general antioxidant claims.
TUDCA, RPE Phagocytosis, and Drusen Formation
A second AMD-relevant mechanism involves phagocytosis. Each day, the RPE must engulf and digest shed photoreceptor outer segment fragments — a process that, when it slows or becomes inefficient with age, is thought to contribute to the buildup of undigested material that forms drusen, the yellow deposits that are a defining early sign of AMD on retinal imaging. Research examining TUDCA’s effect on this process found that TUDCA promotes RPE phagocytosis of photoreceptor outer segments through activation of the MerTK receptor, a key receptor RPE cells use to recognize and engulf shed segments [2].
This finding is notable because MerTK dysfunction is independently implicated in retinal degeneration research, and a compound that supports rather than impairs this clearance pathway is mechanistically distinct from (and complementary to) TUDCA’s antioxidant effects. Together, the phagocytosis-support finding and the oxidative-stress finding above describe two separate ways TUDCA could plausibly support RPE function in aging or stressed retinal tissue — though both remain preclinical.
Photoreceptor Protection: What Carries Over From Retinal Detachment Research
TUDCA’s photoreceptor-protective evidence is strongest in the context of retinal detachment, where photoreceptors become physically separated from the RPE and rapidly undergo apoptosis. A study using a rat model of experimental retinal detachment found that systemic TUDCA administration reduced photoreceptor cell death (measured via TUNEL staining) and preserved outer nuclear layer thickness compared to untreated controls, with the protective effect linked to reduced oxidative stress and caspase activity [4].
The relevance to AMD is indirect but real: advanced (“wet”) AMD can involve subretinal fluid and localized detachment-like separation of photoreceptors from the RPE, and the same apoptotic pathways studied in mechanical detachment models are implicated in AMD-related photoreceptor loss. This is not the same as evidence that TUDCA treats AMD directly, but it adds another point of mechanistic overlap between TUDCA’s established neuroprotective profile and processes that occur in advanced AMD.
The Human Evidence: Oral UDCA and AMD Diagnosis Rates
The most directly relevant human data available does not come from TUDCA studies but from its structurally related parent bile acid, ursodeoxycholic acid (UDCA) — TUDCA is UDCA conjugated with taurine, and the two compounds share overlapping receptor targets and mechanisms, though they are not identical. A 2025 retrospective study examined patients taking oral UDCA (typically prescribed for gallstone disease or cholestatic liver conditions) and found it was associated with a decreased rate of newly diagnosed AMD compared to non-users [3].
This is an association from a retrospective cohort, not a randomized controlled trial designed to test AMD prevention, and it studied UDCA rather than TUDCA specifically — the taurine conjugation that distinguishes TUDCA affects its solubility, potency, and cell-penetration properties, so results cannot be assumed to transfer exactly. It is nonetheless the first population-level signal connecting this bile acid class to real-world AMD outcomes, and it is consistent with (though does not prove) the mechanistic RPE-protective findings above.
Honest Assessment: What the Evidence Can and Cannot Tell Us
TUDCA’s AMD-relevant evidence base is genuinely early-stage: two cell-culture/tissue mechanism studies on RPE oxidative stress and phagocytosis, one animal model of a related but distinct condition (retinal detachment), and one retrospective human association study using a different, related compound (UDCA, not TUDCA). No study has tested oral TUDCA supplementation in humans diagnosed with AMD and measured disease progression, visual outcomes, or drusen burden as an endpoint.
This is a meaningfully different evidence profile from TUDCA’s retinitis pigmentosa research, which includes multiple animal models across different genetic defect types. Readers researching TUDCA specifically for AMD should treat the current evidence as biologically plausible and worth watching, not as established treatment support. AMD management should remain under the direction of an ophthalmologist, and any supplement use should be discussed with that provider given the interacting factors (AREDS2 formulations, anti-VEGF therapy, other medications) already involved in AMD care.
Frequently Asked Questions
Is TUDCA the same as the AMD research on UDCA?
No. UDCA (ursodeoxycholic acid) is the non-taurine-conjugated parent compound; TUDCA is UDCA bonded to taurine. They share overlapping mechanisms but differ in solubility and potency. The retrospective study finding a decreased AMD diagnosis rate studied oral UDCA specifically, not TUDCA [3].
Does TUDCA help with drusen or RPE health specifically?
Preclinical research shows TUDCA can promote RPE phagocytosis of photoreceptor outer segments via MerTK activation [2] and can protect RPE cells from oxidative stress through autophagy induction [1]—both processes relevant to drusen formation and early AMD, but not yet tested as a drusen-reduction treatment in humans.
Is this the same research as TUDCA for retinitis pigmentosa?
No. TUDCA’s retinitis pigmentosa evidence targets photoreceptor apoptosis from inherited gene defects. AMD-relevant research targets the retinal pigment epithelium and is a smaller, more recent, and largely separate body of evidence.
Should I take TUDCA for AMD instead of standard treatment?
No. There is no clinical trial evidence that TUDCA treats or slows AMD in humans. Standard AMD management (AREDS2 supplementation where indicated, anti-VEGF therapy for wet AMD, regular monitoring) should not be replaced or delayed. Discuss any supplement addition with your ophthalmologist, particularly given TUDCA’s contraindications in bile duct obstruction and interactions with certain medications.
References
- Tauroursodeoxycholic Acid Confers Protection Against Oxidative Stress via Autophagy Induction in Retinal Pigment Epithelial Cells. Current issues in molecular biology (2025).
- TUDCA Promotes Phagocytosis by Retinal Pigment Epithelium via MerTK Activation. Investigative ophthalmology & visual science (2015).
- Oral Ursodeoxycholic Acid Is Associated With Decreased Rate of AMD. Clinical therapeutics (2025).
- Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment. PloS one (2011).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
